Skip to Content
Merck
All Photos(7)

Key Documents

AB5622

Sigma-Aldrich

Anti-Microtubule-Associated Protein 2 (MAP2) Antibody

Chemicon®, from rabbit

Synonym(s):

Anti-MAP2 antibody, microtubule-associated protein 2

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

rabbit

Quality Level

antibody form

saturated ammonium sulfate (SAS) precipitated

antibody product type

primary antibodies

clone

polyclonal

species reactivity

rat, mouse, human

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
immunocytochemistry: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

target post-translational modification

unmodified

Gene Information

human ... MAP2(4133)
mouse ... Map2(17756)
rat ... Map2(25595)

General description

The microtubule-associated protein 2 (MAP2) is an abundant neuronal cytoskeletal protein that binds to tubulin and stabilizes microtubules. (Herzog and Weber, 1978). MAP2 is essential for the development and maitenance of neuronal morphology (Matus, 1991). In neurons MAP2 occurs as three primary isoforms, the high molecular weight MAP2a, MAP2b, and the low molecular weight MAP2c, that result from alternative splicing of the MAP2 gene (Chung et al., 1996). The low molecular weight isoform, MAP2c, is expressed in developing brain and is down-regulated during brain maturation, whereas the high molecular weight MAP2b is expressed in both developing and adult brain. The MAP2a appears only after brain maturation (Tucker, 1990). All these forms bind to microtubules through a domain near the carboxyl terminus that contains either three or four similar repeats of a 31-amino-acid motif (Lewis et al., 1988). MAP2 together with MAP4 and tau proteins belong to the family of thermostable proteins associated with microtubules.

Specificity

Anti-MAP2 antibody’s reactivity with other species has not been determined. Anti-MAP2 antibody is specific for Microtubule-associated protein 2 (MAP2). The antibody recognizes all MAP2 isoforms (MAP2A, MAP2B, MAP2C and MAP2D). It shows greatest immunoreactivity with the HMW-MAP2 (MAP2A and MAP2B).

Immunogen

Purified Microtubule-associated protein from rat brain.

Application

Detect Microtubule-Associated Protein 2 (MAP2) using this Anti-Microtubule-Associated Protein 2 (MAP2) Antibody validated for use in ELISA, IC, IH, IH(P) & WB with more than 55 product citations.
Immunocytochemistry:
1:1,000 dilution of a previous lot was used on primary neurons.

Immunohistochemistry:
1:1,000 dilution on 4% paraformaldehyde / PBS fixed tissue sections.

Immunoblot:
1:2,000 dilution was used on a previous lot. Recognizes MAP2A (280-300kDa, and MAP2B (270-280KDa), and to a lesser extent MAP2C (70kDa) and MAP2D (70-75kDa).

ELISA:
greater than or equal to1:2,000 dilution of a previous lot was used.

Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Research Sub Category
Neuronal & Glial Markers

Neurofilament & Neuron Metabolism

Quality

Immunohistochemistry(paraffin) Analysis:
MAP2 (cat. # AB5622) staining on Normal Cerebellum. Tissue pretreated with Citrate, pH 6.0. This lot of antibody was diluted to 1:500, using IHC-Select Detection with HRP-DAB. Immunoreactivity is seen as fiber-like- staining (brown) on microtubule.
Optimal Staining With TE Buffer, pH 9.0, Epitope Retrieval: Human Cerebellum

Target description

Approx. 280 kDa doublet (MAP2a and MAP2b) and approx. 70 kDa doublet (MAP2c) on SDS-PAGE.

Physical form

Ammonium Sulfate Precipitation
Format: Purified
Purified rabbit polyclonal in buffer containing PBS with 0.1% sodium azide as a preservative.

Storage and Stability

Maintain at -20ºC in undiluted aliquots for up to 6 months after date of receipt. Avoid repeatedfreeze/thaw cycles.

Analysis Note

Control
Human brain tissue or human glioblastoma T98G cells

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mitochondrial protection attenuates inflammation-induced impairment of neurogenesis in vitro and in vivo.
Voloboueva, LA; Lee, SW; Emery, JF; Palmer, TD; Giffard, RG
The Journal of Neuroscience null
Anne M Taylor et al.
Neuron, 66(1), 57-68 (2010-04-20)
The polarized nature of neurons and the size and density of synapses complicates the manipulation and visualization of cell biological processes that control synaptic function. Here we developed a microfluidic local perfusion (microLP) chamber to access and manipulate synaptic regions
Chengrui Nan et al.
International journal of molecular medicine, 36(4), 1057-1062 (2015-08-12)
In the present study, human umbilical cord-derived mesenchymal stem cells (hUMSCs) were investigated for their potential to be induced to differentiate in vitro into neuron-like cells by monosialoteterahexosyl ganglioside (GM1). Mononuclear cells obtained from umbilical cords from women with full-term pregnancies whose babies
Manuela Mellone et al.
Frontiers in cellular neuroscience, 9, 245-245 (2015-07-29)
Levodopa-induced dyskinesias (LIDs) are major complications in the pharmacological management of Parkinson's disease (PD). Abnormal glutamatergic transmission in the striatum is considered a key factor in the development of LIDs. This work aims at: (i) characterizing N-methyl-D-aspartate (NMDA) receptor GluN2A/GluN2B
Neil G Harris et al.
Journal of neuropathology and experimental neurology, 69(2), 139-154 (2010-01-20)
We previously reported that pericontusional extracellular chondroitin sulfate proteoglycans (CSPGs) are profoundly reduced for 3 weeks after experimental traumatic brain injury, indicating a potential growth-permissive window for plasticity. Here, we investigate the extracellular environment of sprouting neurons after controlled cortical

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service